Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

Dr. Guglietta: Yes. So, it's exactly the challenge. And what we are actually seeing is that at the moment, especially for ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Landscape of MET genomic alterations in colorectal cancer (CRC). VEGF-A as a prognostic indicator in advanced gastric and colorectal cancers and correlation with immune suppression involving ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy.

Bristol Myers Squibb (BMS) has shared promising results from a late-stage study of its dual immunotherapy combination in ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

The market is responding to this breakthrough. Analysts at Exactitude Consultancy predict that the global immunotherapy ...